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Abstract
Dendritic cells (DCs) are part of the innate immune system with a key role in initiating and modulating T cell
mediated immune responses. Coeliac disease is caused by inappropriate activation of such a response leading to
small intestinal inflammation when gluten is ingested. Tissue transglutaminase, an extracellular matrix (ECM)
protein, has an established role in coeliac disease; however, little work to date has examined its impact on DCs.
The aim of this study was to investigate the effect of small intestinal ECM proteins, fibronectin (FN) and tissue
transglutaminase 2 (TG-2), on human DCs by including these proteins in DC cultures.
The study used flow cytometry and scanning electron microscopy to determine the effect of FN and TG-2 on
phenotype, endocytic ability and and morphology of DCs. Furthermore, DCs treated with FN and TG-2 were
cultured with T cells and subsequent T cell proliferation and cytokine profile was determined.
The data indicate that transglutaminase affected DCs in a concentration-dependent manner. High concentrations
were associated with a more mature phenotype and increased ability to stimulate T cells, while lower
concentrations led to maintenance of an immature phenotype.
These data provide support for an additional role for transglutaminase in coeliac disease and demonstrate the
potential of in vitro modelling of coeliac disease pathogenesis.
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Background
Dendritic cells (DCs) are part of the innate immune sys-
tem with a vital role in modulating adaptive immune
responses [1,2]. DCs have a life cycle consisting of two
distinct phases [2]. In the immature state, they act as
sentinels and are particularly concentrated in areas of
microbial exposure, where they take up and process
antigens for presentation by MHC molecules [3]. Once
activated, by ligation of pattern-recognition receptors,
they begin to mature and migrate to local lymph nodes
[2]. In lymph nodes, they present antigens to specific T-
helper (Th) cells that, together with other factors such
as cytokine microenvironment, determine the
differentiation of T cells to one of several specialised
subsets, such as Th1, Th2, Th17 or Treg. [2,4]. DCs are
particularly important for the induction of naïve Th
responses owing to their abundant surface expression of
co-stimulatory molecules such as CD80 and CD86 [3-5].
DCs are also thought to play an important role in indu-
cing and controlling tolerance in the periphery [6]. T
cells that interact with immature DCs, which have low
surface expression of co-stimulatory molecules [2], are
likely to undergo apoptosis, become anergic (immunolo-
gically unresponsive) or differentiate to a regulatory phe-
notype [6].
DCs have an important role in modulating T cell
mediated immune responses [2], and therefore factors
affecting their function have significance for all adaptive
immune responses. A recent study [1] found that extra-
cellular matrix (ECM) components, particularly laminin
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and fibronectin (FN), have an impact on DC phenotype
and function. DCs interact with ECM via integrins and
it is suggested that through this signalling pathway,
laminin and FN maintain DCs in an immature pheno-
type, with high surface expression of endocytic receptors
and low expression of molecules needed for T cell sig-
nalling [1,7]. Another ECM protein with a putative role
in determining DC phenotype is tissue transglutaminase
2 (TG-2) [8]. TG-2 is a member of the transglutaminase
enzyme family, which comprises several important
enzymes involved in protein cross-linking [9]. TG-2 is
already known to have a role in DC function [8,10],
although the full details of its role are yet to be deter-
mined. DCs have been found to increase the expression
of TG-2 as their life cycle progresses, with particularly
high levels during the final stages of maturation [10].
TG-2 may also play a part in DC maturation in
response to LPS stimulation; recent research found
increased levels of TG-2 subsequent to encountering
LPS [8]. This research also indicated that DCs in mice
lacking TG-2 may be unable to fully mature (following
LPS stimulation), and therefore have reduced capacity to
stimulate CD4+ T cell, in particular Th1, responses [8].
These findings provide interesting insights into the
potential role of TG-2 in DC function and maturation,
but give considerable scope for further investigation into
the nature of its part in determining signals delivered by
DCs to T cells and the resulting effect on T cell
mediated responses.
TG-2 is also involved in the pathogenesis of coeliac
disease [11-13], with well-established roles both in
increasing the immunogenicity of gluten antigens and
also as an autoantigen [11], against which autoantibodies
are directed. Coeliac disease is an immunological condi-
tion, provoked by ingestion of gluten, in which inflam-
mation of the small intestine (in genetically predisposed
individuals) is mediated by T cells specific for gluten-
derived antigens [13]. Interestingly, previous studies
have indicated that T cells specific for these antigens
can be found in the peripheral blood of both healthy
individuals as well as coeliac disease patients [14,15].
DCs serve as the major antigen presenting cells to T
cells [2], stimulating protective and, in the case of coe-
liac disease, pathological adaptive immune responses.
TG-2 is expressed in the small intestine, with raised
levels in coeliac disease [12], and it is therefore possible
that TG-2 interacts with DCs to contribute to the
pathogenesis of coeliac disease, for example, by increas-
ing the ability of DCs to stimulate T cell-mediated
responses.
The aim of this study was to characterise the effect of
TG-2 on DCs. By including TG-2 in monocyte derived
DC cultures at early stages of their differentiation, the
study sought to investigate what effect it might have on
DC phenotype, morphology and function. The study
also aimed to investigate the role of TG-2 in coeliac dis-
ease by assessing whether TG-2 affected the ability of
DCs to stimulate naïve T cells in response to gliadin,
the major antigen found in gluten.
Methods
Ethics statement
Peripheral blood mononuclear cells were separated from
buffy coat preparations obtained from National Blood
Service (Sheffield, UK) following institutional ethics
guidelines.
Generating DCs
Monocyte isolation and generation of DCs was carried
out as described previously [1]. Briefly, heparinised
whole blood was layered on Histopaque (Sigma, Irvine,
UK) and centrifuged in order to fractionate blood for
collection of PBMCs. Monocytes were isolated from
PBMCs using anti-CD14 microbeads (Miltenyi-Biotec,
Bergisch Gladbach, Germany). Purified monocytes were
then suspended in medium consisting of 250 U/mL
recombinant human (rh) IL-4 (R&D systems, Oxford,
UK) and 50 ng/mL rhGM-CSF (R&D systems) in com-
plete RPMI medium (10% FBS, 2 mM L-glutamine and
1% penicillin/streptomycin in RPMI). Cells were then
cultured in 12-well plates for 6 days.
Expression of cell surface markers
Expression of cell surface markers was assessed by addi-
tion of monoclonal antibodies, conjugated to the fluoro-
phores FITC, PE or PC5, with specificity for cell surface
markers. The selection of antibodies used depended on
the markers of interest in each experiment and was cho-
sen from the following: FITC-CD80 (clone MAB104,
IgG1, Beckman Coulter), PC5-CD83 (clone HB15a,
IgG2b, Beckman Coulter), PE-CD86 (clone HA5.2B7,
IgG2b, Beckman Coulter), PE-CD206 (clone 3.29B1.10,
IgG1, Beckman Coulter), PE-CD209 (clone AZND1,
IgG1, Beckman Coulter), PC5-HLA-DR (Immu-357,
IgG1, Beckman Coulter), FITC-CD54 (clone 84 H10,
IgG1, Beckman Coulter) and PE-CD11c (clone BU15,
IgG1, Beckman Coulter). Additionally, isotype controls
were set up to control for non-specific binding. The fol-
lowing isotype controls were added, where relevant:
FITC-IgG1 (Beckman Coulter), PE-IgG1 (Beckman
Coulter), PC5-IgG1 (Beckman Coulter) and FITC-IgG2a
(Beckman Coulter). One sample also remained
unstained to provide an assessment of auto-fluorescence.
Cells were first washed with PBA (1% BSA (Sigma)
and 0.02% sodium azide in PBS). 5 μL of each of the
antibodies of interest was added to the cells and the
resulting suspension mixed thoroughly before incubation
for 30 min at 4°C in the dark. Cells were then washed
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with PBA, fixed by addition of 0.5% formaldehyde
(Sigma) in PBS and then stored at 4°C until samples
were analysed by flowcytometry.
Collection and analysis of surface marker expression data
Data on cell surface marker expression were collected
using a Beckman Coulter EPICS Altra™ (Beckman
Coulter, High Wycombe, UK). Data were gated to
include only cells of interest in the analysis, on the basis
of forward and side scatter. The mean fluorescence
intensity (MFI) value for each marker was recorded and
the MFI value for the relevant isotype or unstained con-
trol was subtracted, to adjust for background
fluorescence.
Transglutaminase activity assay
Transglutaminase enzymatic activity was determined
using a modified version of the hydroxamate assay pre-
viously described by Folk and Chung [16]. Briefly, a 25
μl portion of TG solution was mixed with 75 μl of
Reagent A (0.2 M sodium acetate (pH 6.0), 0.03 M
CBZ-Gln-Gly, 0.1 M hydroxylamine, 0.01 M glutathione,
5 mM CaCl2 and 5 mM DTT) in a well of a 96-well
plate. Following incubation at 37°C for 10 min and to
terminate the reaction, 75 μl of Reagent B (1 volume of
3 N HCl, 1 volume 12% trichloroacetic acid and 1
volume 5% FeCl3.6H2O (dissolved in 0.1 N HCl)) was
added to the well. The resultant absorbance (492 nm)
was measured using an Optima FLUOstar® plate reader
(BMG LabTech, Aylesbury, UK). A unit of transglutami-
nase activity is defined as the amount of enzyme catalys-
ing the formation of 1 μmol of hydroxamic acid per
minute under the described reaction conditions.
Treating DCs with ECM proteins
In order to assess the effect of ECM protein treatment
on DCs, cell culture plates were first coated with ECM
proteins, followed by addition of DCs and assessment of
markers of DC function at subsequent time points. 48-
well plates (Corning Life Sciences) were coated with
ECM proteins by addition of one of the following pro-
tein solutions: 0.01% FN (Sigma) in PBS, tissue transglu-
taminase 2 (TG-2; Sigma) at 0.039 U/mL (TG-2 [high]),
0.0036 U/mL (TG-2 [mid]) or 0.00022 U/mL (TG-2
[low]) in PBS to wells. Additionally, a PBS control and a
BSA (1% in PBS; Sigma) control were set up. Plates
were incubated at 37°C for 24 h. Each of the wells was
then washed twice with cold PBS, before adding DCs in
complete RPMI medium to each well. Cells were incu-
bated at 37°C and assessed at 48 h and 72 h for cell via-
bility and by flow cytometry (as described previously)
for expression of the following surface markers: CD11c,
CD80, CD86, CD83, HLA-DR, CD206, CD209 and
CD54. Additionally, endocytic ability of cells after 48 h
treatment was determined, as described below, and
levels of IL-1a, IL-6, IL-8, IL-10 and IL-12 in culture
supernatants were measured using the cytokine assay
described below.
Endocytosis
Assessment of DC endocytic ability was performed by
measuring uptake of FITC-dextran (Invitrogen, Carls-
bad, CA). DCs were first washed with PBS, followed by
suspension in ice cold serum-free RPMI medium. The
resulting suspension was then distributed evenly
between four eppendorfs. FITC-dextran was added to
two of the samples to a concentration of 1 mg/mL,
while two remained untreated. One each of the FITC-
dextran treated and untreated samples was then incu-
bated in reduced light either at 37°C or at 4°C for 1.5 h.
Following incubation, cells were washed with serum-free
RPMI medium and subsequently with PBS. Finally, cells
were fixed by addition of 0.5% formaldehyde in PBS and
stored at 4°C until data collection was performed. Data
were collected and analysed by flow cytometry as
described previously. Data were gated on the basis of
forward and side scatter to exclude dead cells.
Scanning electron microscopy imaging (SEM)
Cells were treated with ECM proteins for 48 h as
described above. Following treatment, cells were washed
with PBS and then prepared for SEM imaging, as
described elsewhere [17]. Briefly, samples were mounted
onto aluminium SEM stubs using double-sided carbon
tape and then gold coated, for 3 min, under an argon
atmosphere before being imaged using a variable pres-
sure JOEL JSM-6060LV SEM (Jeol, Tokyo, Japan) oper-
ating at an accelerating voltage of 10 kV. Image analysis
was carried out using the in-built SEM Control User
Interface software (version 6.57) and digital imaging
system.
Culturing ECM-treated DCs with T cells
DCs, pre-treated with different ECM proteins for 48 h
as described previously, were cultured with autologous
naïve T cells in order to establish the effect of ECM
treatment on DC induction of a T cell response. Naïve
T cells were isolated from CD14 depleted PBMCs, col-
lected during the original positive selection of CD14+
PBMCs from which DCs were generated. In a two-step
process, T cells were isolated from CD14 depleted
PBMCs using a Pan T cell Kit (Miltenyi Biotec) and
memory T cells were depleted on the basis of CD45RO
expression, a memory T cell marker [18], using anti-
CD45RO microbeads (Miltenyi Biotec). ECM treated
DCs cells were incubated at 37°C for 45 min with glia-
din (MP Biomedicals, Illkirch, France; 0.1% w/v in PBS
with 0.1% v/v DMSO (Sigma)). Control DCs received no
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antigen. Following incubation, DCs were washed twice
with PBS and autologous naïve T cells were added to
DCs at a ratio of 5:1 (T cells to DC). DCs were also cul-
tured without T cells where DCs received equal volume
of T cell medium (RPMI enriched with 10% v/v serum
from the original donor as well as 2 mM L-glutamine
and 1% v/v penicillin/streptomycin), containing no T
cell. Additionally, a culture of naïve T cells without DCs
was established. Cells were incubated at 37°C for 5 days.
Supernatant was collected on day 5 and used to mea-
sure production of IFN-g, IL-4, IL-10, IL- 12 and IL-13
using the cytokine assay described below. The cells were
then washed with PBS and used in a T cell proliferation
assay as described below.
T cell proliferation
In order to determine T cell proliferation, incorporation
of BrdU, an analogue of thymidine, into DNA in divid-
ing cells was measured. Proliferation was measured
using the BrdU Cell Proliferation Assay (Merck Chemi-
cals, Nottingham, UK) carried out according to manu-
facturer’s instructions.
Cytokine assay
To assess the levels of cytokines released from cells,
supernatant was collected and cytokines measured with
a bead assay using FlowCytomix™ Basic and Simplex
Kits (Bender MedSystems, Vienna, Austria). The assay
was performed according to manufacturer’s instructions
and measured cytokines from a selection chosen from
the following: IFN-g, IL-4, IL-10, IL-12 and IL-13. Fol-
lowing assay preparation, data were collected using a
Beckman Coulter FC500 and were analysed using Flow-
Cytomix Pro 2.4 Software (Bender MedSystems).
Statistical analysis
Means and standard deviations were calculated for each
sample and differences between the means were com-
pared using the Student t-test (two-tailed); p < 0.05 was
considered significant.
Results
Pre-treatment with transglutaminase changed DC surface
marker profile
Enzymatically active TG-2, the activity of which was
quantified by the hydroxamate assay (data not shown),
was associated with dose-dependent changes in DC phe-
notype following 48 and 72 h of co-culture, as charac-
terised by flow cytometry. Figure 1 demonstrates that
culture of immature DCs with TG-2 [high] (0.039 U/mL
TG-2) for 72 h led to a significant increase in some
maturation markers (CD83, HLA-DR). Co-culture of
DCs with TG-2 [mid] (0.0036 U/mL TG-2) was asso-
ciated with significantly reduced CD86 expression at 48
h. Immature DCs which were exposed to TG-2 [low]
(0.00022 U/mL TG-2) in culture had significantly
reduced expression of CD86 and HLA-DR (P < 0.01) at
48 h and, additionally, a significantly lower expression of
CD86 (P < 0.001) and CD54 at 72 h. Culturing in differ-
ent conditions did not significantly affect cell viability
[data not shown].
Transglutaminase increased DC endocytic ability and
altered cell morphology
Endocytic ability is key to the function of immature
DCs, allowing capture of antigens for later presentation
to T cells. Uptake of FITC-dextran by DCs cultured
with different concentrations of TG-2 was used to quan-
tify endocytic ability. Figure 2 demonstrates that treat-
ment with TG-2 [mid] or TG-2 [low] for 48 h
significantly (P < 0.05) increased the endocytic ability of
DCs. TG-2 [high] showed large variability in its effect,
showing a wide standard deviation, implying little effect
on the endocytic ability of DCs. TG-2 also affected the
morphology of DCs, in a concentration-dependent man-
ner, as shown in Figure 3. TG-2 [high] was associated
with a reduced number of dendrites but which were
longer in comparison with TG-2 [mid] and TG-2 [low].
TG-2 [mid]-treated DCs had long, broad dendrites,
while TG-2 [low] lead to more numerous, but shorter
and thinner dendrites.
Transglutaminase had a concentration-dependent effect
on DC induction of T cell proliferation and cytokine
profiles
To establish whether observed changes in phenotype
and function might have an effect on DC induction of T
cell responses in either mixed-lymphocyte reaction
(MLR) or antigen-specific (DCs loaded with gliadin, the
major gluten antigen) systems, TG-2- treated DC were
cultured with autologous naïve T cells and T cell prolif-
eration (Figure 4) and production of IFN-g, IL-13 and
IL-10 were measured (Figure 5). TG-2 showed a con-
centration-dependent effect on the induction of naïve T
cell proliferation by DCs. The data indicate that, as
expected, naïve T cells were unable to proliferate in the
absence of DCs, as shown by the low BrdU absorbance
for T cell only cultures. Naïve T cells co-cultured with
TG-2 [high]-treated DCs in a MLR experiment showed
increased proliferation compared to those co-cultured
with untreated (control) DCs. These T cells also
appeared to produce larger amounts of IFN-g and IL-13,
while IL-10 production was reduced. TG-2 [mid]-treated
DCs showed reduced induction of naïve T cell in an
MLR experiment, while TG-2 [low]-treated DCs
appeared to be slightly enhanced in induction of naïve T
cells. TG-2 [mid]- and TG-2 [low]-treated DCs seemed
to reduce IL-10 production by naïve T cells in co-
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culture. Interestingly, treatment with both concentra-
tions was associated with a small increase in production
of IL-10 by DCs, however. Neither TG-2 [mid] nor TG-
2 [low] treatments seemed to have an effect on DC
induction of IFN-g or IL-13 production by naïve T cells
in MLR experiments.
Proliferation of naïve T cells appeared to be further
enhanced when these cells were cocultured with gliadin-
loaded TG-2 [high]-treated DCs. Co-culturing of naïve
T cells with TG-2 [low]-treated DCs loaded with gliadin
also increased T cell proliferation, while T cell prolifera-
tion was reduced in co-culture with TG-2 [mid]-treated
gliadin loaded DCs. When naïve T cells were cultured
with TG-2 [high]-treated DCs which had been loaded
with gliadin, IFN-g and IL-13 production by T cells
were raised considerably. At the same time, IL-10
production by naïve T cells was reduced. IFN-g and IL-
13 production by naïve T cells were unaffected when
these cells were in co-culture with TG-2 [mid]- or TG-2
[low]-treated DCs, loaded with gliadin. Naïve T cell pro-
duction of IL-10 was reduced in co-culture with gliadin-
loaded DCs previously treated with TG-2 [mid] or TG-2
[low]. However, under similar conditions, TG-2 [low]-
treated DCs appeared to produce substantially more IL-
10 than control DCs. IL-12 was not detected in any
samples, while levels of IL-4 were negligible and produc-
tion by naïve T cells was unaffected by co-culture with
TG2treated DCs (data not shown).
Discussion
The observations in this study (summarised in Table 1)
demonstrate that DCs cultured with different
Figure 1 Analysis of DC phenotype following treatment with ECM proteins. (A) Flow cytometric analysis of the phenotype of untreated
(control) DCs following culturing for 48 h (upper panel) and 72 h (lower panel). The filled histograms represent isotype or unstained controls,
unfilled histograms show staining of named markers. The numbers are MFI values of a representative experiment (B) Phenotype of DCs
untreated (CTRL) or treated with 0.01% FN, TG [high], TG [mid] or TG [low] for 48 h (upper panel) and 72 h (lower panel), (n = 3). MFI values for
the indicated antigens are depicted as a percentage of the CTRL value. TG-2 activity defined as 0.039 U/mL (TG-2 [high]), 0.0036 U/mL (TG-2
[mid]) or 0.00022 U/mL (TG-2 [low]). Error bars represent standard deviations and * p < 0.05, ** p < 0.01, *** p < 0.001. NB: n = 2 for CD54
expression.
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concentrations of TG-2 showed changes in their pheno-
type, function and induction of T cell activation at dif-
ferent timepoints. TG-2 used in this study was a
commercial preparation derived from guinea pig liver
and demonstrated a high degree of enzymatic activity. It
has previously been reported that human TG-2 and TG-
2 from guinea pig liverare highly comparable in detec-
tion of human anti-TG2 autoantibodies when used in a
diagnostic test for coeliac disease [19]. Therefore, it was
reasonable to assume that the two proteins are similar
enough for the effects of guinea pig TG-2 on DCs to be
comparable to those of human TG-2. However, given
that more recently human TG-2 has become more read-
ily available future work in this area would clearly bene-
fit from the use of human TG-2 in such experiments.
Moreover, how the activity of the commercial prepara-
tion of TG-2 corresponds to the activity of TG-2 in the
human small intestine is poorly established; indeed little
is known about the activity and levels of TG-2 in the
small intestine. Thus, a range of TG-2 concentrations
was used to screen for the effect of TG-2 on DCs.
Establishing the range of TG-2 concentration in the
small intestine in normal and coeliac patients would
therefore be extremely beneficial for studies in this area.
The data in this study show that DCs cultured with
TG-2 gained a different phenotype compared to control
DCs, and also compared to DCs treated with FN, a
structural ECM protein. The data indicate that TG-2
acted in a concentration-dependent manner, with differ-
ent surface marker profiles associated with each of the
concentrations of TG-2. The function of immature DCs
is to capture antigens and, once activated by molecular
patterns associated with pathogens, to migrate to lym-
phoid tissue where they activate T cells [2]. Thus,
immature and mature DCs can be contrasted on the
basis of their surface phenotype and certain functional
properties [20]. While immature DCs are associated
with high levels of endocytic receptors, such as CD206
and CD209, and thus show enhanced endocytic ability
[20], mature DCs have high expression of molecules
required to interact with and stimulate T cells - MHC
class II (HLA-DR), co-stimulatory molecules (CD80,
CD86), the adhesion molecule, CD54 (2) and the matur-
ity marker, CD83 [20,21]. The data demonstrate that
DCs cultured with high concentration TG-2 gained a
more mature phenotype, as shown by increased
Figure 2 Endocytic characteristics of DCs following treatment
with ECM proteins. Endocytic ability of the DCs, at 48 h, was
assessed by the uptake of FITC-dextran using flow cytometry (n =
2). Data were gated, based on forward/side scatter characteristics
and on FITC channel to exclude dead cells and contaminating
clumps of FITC-dextran. Error bars represent standard deviations. * p
< 0.05. NB: Statistical analysis is based on differences between
means of untreated control (CTRL) and treated samples. Sample
treatments correspond to untreated (CTRL), 0.01% FN, 1% BSA and
TG-2 activity defined as 0.039 U/mL (TG-2 [high]), 0.0036 U/mL (TG-2
[mid]) or 0.00022 U/mL (TG-2 [low]).
Figure 3 Scanning electron microscopy (SEM) images of DCs
following treatment with ECM proteins. Dendritic cells, following
48 h treatment with TG[high], TG [mid] or TG [low] were mounted
onto aluminium stubs, gold coated under an argon atmosphere
before being imaged using a JOEL 6060LV variable pressure SEM
operating at 10 kV accelerating voltage at x750 and x1500
magnifications (n = 1). Sample treatments correspond to untreated
(CTRL) and TG-2 activity defined as 0.039 U/mL (TG-2 [high]), 0.0036
U/mL (TG-2 [mid]) or 0.00022 U/mL (TG-2 [low]).
Figure 4 T-cell proliferation in response to co-culture with
treated DCs. Naïve T-cell proliferation was assessed following 5
days of culture with pre-treated DCs (48 h and loaded with gliadin)
(n = 1). Samples include naïve T-cell cultured in a mixed
lymphocyte reaction (MLR) and treated DCs, and naïve T cells in
single culture. Absorbance values for DCs in single culture were
subtracted to give the values shown. Sample treatments correspond
to untreated (CTRL) and TG-2 activity defined as 0.039 U/mL (TG-2
[high]), 0.0036 U/mL (TG-2 [mid]) or 0.00022 U/mL (TG-2 [low]).
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expression of maturation markers (CD83, MHC class II)
after 72 h culturing. The data may indicate initiation of
this maturation process at 48 h by high concentration
TG-2, where there was an almost significant increase in
expression of the maturation marker CD83, although
other markers were unaffected. However, the presence
of lower concentrations of TG- 2 was associated with
the converse effect. DCs appeared to acquire a more
immature phenotype when cultured with lower concen-
trations of TG-2 (TG-2 [mid]/TG-2 [low]), which is
demonstrated by a reduction in the expression of mar-
kers of maturation at 48 h (CD86, MHC II) and 72 h
(CD83, CD54) and also by enhancement of endocytic
ability of DCs.
Furthurmore, our data indicate that the presence of
TG-2 affected DC morphology. DCs cultured with high
concentration TG-2 had a reduced number of dendrites,
but which were longer and thinner in comparison to
lower concentrations of TG-2. The presence of lower
concentrations of TG-2 resulted in DCs having a con-
siderable number of very short dendrites. Dendrites are
important in several aspects of DC function. Immature
DCs have less pronounced dendrites and these extru-
sions of the cell surface are thought to contribute to
increasing surface area as a means of augmenting the
efficiency of antigen uptake [22]. On the other hand, the
long dendrites associated with mature DCs [22] may be
involved in allowing DCs to form interactions with a
multitude of T cells with distinct specificities within
lymphoid tissue, in order to initiate adaptive immune
responses with high efficiency. Thus, DCs treated with
high concentration may have taken on a more mature
morphology, while treatment with lower concentrations
may have led to a more immature morphology, which
clearly supports the data collected on surface phenotype.
The role of DCs in vivo is to stimulate adaptive
immune responses, by presenting antigens to T cells [2].
DCs treated with high concentration TG-2 were amelio-
rated in their ability to trigger proliferation of naïve T
Figure 5 Cytokine expression profile of naïve T cells in co-culture with dendritic cells. Cytokine production from co-culture of naïve T cells
and DCs following treatment with TG as previously described (n = 1). Concentrations (pg/ml) of IFN-g (A), IL-13 (B) and IL-10 (C) in supernatant
following co-culture of naïve T cells with DCs in a mixed lymphocyte reaction (MLR) (upper panel) or co-culture of naïve T cells with DCs which
had been loaded with gliadin. Also depicted is cytokine production by naïve Tcells and DCs in single culture. Treatments correspond to
untreated (CTRL), 1% BSA and TG-2 activity defined as 0.039 U/mL (TG-2 [high]), 0.0036 U/mL (TG-2 [mid]) or 0.00022 U/mL (TG-2 [low]).
Table 1 A summary of the effects of ECM protein
treatment on DC phenotype, morphology and function
FN TG [high] TG [mid] TG [low]
Surface marker profile
Antigen-presentation (HLA-DR) - ↑*72 - ↓*48
Co-stimulation (CD86) - - ↓*48 ↓*
Endocytosis (CD206) - - - -
Maturity (CD83) - ↑*72 - -
Adhesion (CD54) ↑ - ↓ ↓*72
Morphology - Mature - Immature
Function
Endocytic ability ↑ - ↑* ↑*
T-cell stimulation - ↑ ↓ ↓
T-cell polarisation - Effector Tolerance -
* indicates that change was significantly different from the control. For
phenotypic results, *48 indicates significance only at 48 h, *72 indicates
significance only at 72 h
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cells in an MLR experiment. Their ability was further
increased by antigen loading in the form of gliadin (the
major gluten antigen). DCs treated with high concentra-
tion TG-2 showed a more mature surface phenotype,
which could account for the observed increases in T cell
proliferation. Cytokine production data from the same
experiment supported these observations. The data indi-
cated that DCs pre-treated with high concentration TG-
2 led to high-level cytokine production by T cells, char-
acteristic of an effector T cell response, both in MLR
experiments and when these DCs had been loaded with
gliadin. The balance of T cell cytokines is important in
determining the nature of an effector T cell response,
since T cell subsets display reciprocal regulation [23];
initiation of a potent Th1 response, leading to high-level
IFN-g production prevents Th2 expansion [18]. Simi-
larly, rapid early proliferation of Th2 cells, leading to
cytokines such as IL-4 and IL-13 [4], inhibits Th1 devel-
opment and both Th1 and Th2 subsets are thought to
inhibit Th17 expansion [18]. However, polarisation of a
specific T cell response towards a particular subset is
only thought to become dominant in long-standing
infections [18] and therefore early naïve T cell responses
are likely show more mixed cytokine profiles, which
were evident in this study. Moreover, it has previously
been reported that in healthy subjects, stimulation of
naïve T cells with gliadin results in generation of a Th0
type response, represented by a mixed cytokine profile
[15].
Treatment of DCs with lower concentrations of TG-
2 was associated with a decrease in naïve T cell prolif-
eration, both in MLR experiments and when the TG-
2-treated DCs had been loaded with gliadin. Interac-
tion of naïve T cells with immature DCs, where anti-
gens are presented without co-stimulation, is
associated with induction of anergy or tolerance [6,18].
Culturing DCs with low concentrations of TG-2 led to
a more immature DC phenotype. These data may indi-
cate, therefore, that the DCs which had been pre-trea-
ted with low concentration TG-2 induced anergy in T
cells with which they interacted. Treatment with lower
concentrations of TG-2 (TG-2 [mid]/TG-2 [low]) also
resulted in increased DC production of IL-10, although
T cell production of IL-10 was slightly reduced. IL-10
is an anti-inflammatory cytokine associated with regu-
latory T cells (Treg) [18], which serve to limit the
inflammation caused by effector T cell-mediated
responses, in particular those mediated by Th1 cells
[6,18]. It has also been found that IL-10 is required for
promoting tolerance in the intestinal immune system,
mediated by Treg cells [24]. Interestingly, IL-10 pro-
duction by T cells was considerably reduced when they
were cultured with TG-2 [high]-treated DCs. Taken
together, these data could indicate that DCs exposed
to low concentration TG-2 were tolerogenic, whereas
exposure to high concentration TG-2 breaks this toler-
ance, leading to induction of T cell responses.
Although these results represent data from only one
experiment, they do support other findings from this
study and provide an indication of the effect of TG-2
pre-treatment on DC stimulation and polarisation of
naïve T cells. In future work, it would be worthwhile
to ascertain the effect of TG-2 treatment on DC ability
to induce a Th17 response, by measuring IL-17 levels
in a similar co-culture experiment, particularly given
the emerging importance of Th17 cells in autoimmune
disease [25]. Additionally, a co-culture experiment over
a longer time course would be beneficial.
TG-2 is an enzyme involved in cross-linking proteins
containing glutamine residues, with a physiological role
in ECM stabilisation, in part by giving rise to resistance
to degradation [26]. Interestingly, a recent study found
that an intact ECM is associated with promoting T cell
tolerance [27]. Although this study looked at the effect
of an intact ECM directly on T cells, it would be reason-
able to speculate that the stability of the ECM, to which
TG-2 contributes, could also have a tolerogenic effect
on DCs. Several possible mechanisms for the extra-cel-
lular effects of TG-2 on DCs found in this study are
also plausible. Previous work has looked at the interac-
tion between TG-2 and integrins, particularly as a med-
iator between these molecules and fibronectin [28]. It
has also been reported that the integrins (b1 and b3),
with which TG-2 is able to interact, are expressed by
DCs [2,29,30]. In this way they may affect cell adhesion
and migration - one previous study reported that b1
integrins can affect DC morphology [31]. Interactions
with the extra-cellular matrix may also be important. In
recent work, the effect of DC adhesions on phenotype
was studied [30]. This study found that the increased
strength of DC adhesion to the ECM resulted in greater
pro-inflammatory properties, with an increase in the
expression of maturation markers and release of pro-
inflammatory cytokines. TG-2 also interacts with surface
G-protein-coupled receptors to modulate intracellular
protein kinase pathways, which have the potential to
alter DC intracellular processes [28,32]. TG-2 is also
able to convert TGF-b from an inactive to an active
form [33], which might contribute to TG-2’s effects on
the ECM and perhaps also immune responses. Deci-
phering how these processes could interact to explain
the results in this study is complex. It is conceivable
that at least two systems are at work, with differing affi-
nities for TG-2, which could explain the dose-dependent
effects noted. For example, a high-affinity system leading
to greater endocytosis, keeping DCs in a surveillance
role and a low-affinity system leading to maturation and
migration, which is able to dominate the high-affinity
Dalleywater et al. BMC Immunology 2012, 13:20
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system. Studying these mechanisms would be an extre-
mely informative area of investigation in future work.
Dysregulation of TG-2 is implicated in the pathogen-
esis of several diseases such as coeliac disease and neu-
rodegeneration [9]. Although the enzymatic activity of
TG-2 and, to some extent, its physiological roles in
ECM stabilisation, apoptosis and interactions between
cells and the ECM are well-established, less is known
about its interactions with pathological processes [9].
TG-2 has previously been identified as an autoantigen
in coeliac disease [11] and antibodies directed against it
can be detected as the basis of a diagnostic test for coe-
liac disease [34]. TG-2 is found in the small intestinal
submucosa of both healthy subjects and also those with
coeliac disease, and levels of it are elevated in the small
intestine of those with coeliac disease [12]. The abdom-
inal symptoms and malabsorption found in coeliac dis-
ease are caused by inflammation of the small intestine
which results in loss of villi [35]. The inflammation
associated with coeliac disease is mediated by IFN-g
[18], released by Th1 cells specific for gluten-derived
antigens [13]. These T cells in turn are stimulated by
DCs, the function of which is to serve as a link between
the innate and adaptive immune systems. Thus, pro-
cesses which alter interactions between DCs and T cells
are of potential interest in determining the pathogenesis
of conditions such as coeliac disease.
In the context of coeliac disease, data in this study
may support a model in which low concentrations of
TG-2, in the healthy small intestine, promote tolerance
to gut antigens, such as gluten, therefore preventing T
cell mediated responses associated with autoimmune
disease [36]. Previous work has found that levels of TG-
2 are raised in the small intestine of coeliac disease
patients [12]; it is possible that this is associated with
damage to the gut epithelium causing release of TG-2
either from sequestration or as a cellular stress response
[12]. The resulting high concentrations of TG-2 may
then alter DC phenotype, as observed in this study, lead-
ing to an enhanced ability to trigger T cell responses to
gluten antigens. Autoantibodies to TG-2 generated dur-
ing the adaptive response [11] may then cause further
damage and release of TG-2 leading to a vicious circle
of inflammation. Aspects of this model might be applic-
able in other immunologically-mediated conditions in
which DCs have a role or may have a more general role
in the initiation of an immune response. Clearly, it will
be necessary to do further work to clarify the effect of
TG-2 on DCs, in particular to examine the mechanisms
by which TG-2 interacts with, and alters, DC phenotype
and function. It would also be of interest to repeat
experiments carried out in this study using DCs from
coeliac disease patients in order to develop a more com-
prehensive model of the interactions between TG-2 and
DCs involved in the pathogenesis of coeliac disease in
vivo. Modelling of these interactions could be of poten-
tial benefit in developing a better understanding of the
processes which give rise to coeliac disease and also of
therapeutic benefit in treating coeliac disease, a condi-
tion for which currently the only therapy is to exclude
gluten from the diet [13].
Conclusions
This study indicates that tissue transglutaminase has a
concentration-dependent effect on DCs; higher concen-
trations were associated with a more mature phenotype
and increased ability to stimulate T cells, while lower
concentrations led to maintenance of an immature phe-
notype. While further work will be required to elucidate
the molecular basis of observed transglutaminase
induced changes in DCs, these data provide support for
an additional role for transglutaminase in coeliac disease
and demonstrate the potential of in vitro modelling of
certain aspects of coeliac disease pathogenesis.
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